Happy Administrative Professionals Day! Today is a reminder to acknowledge and celebrate the invaluable contributions of individuals who often work tirelessly behind the scenes. Their professionalism, adaptability, and positive attitude make a significant difference! Thank you 🩵

Join us 5/10 for the Annual Cancer Disparities Research Symposium!

Hosted by Christopher Lathan, MD, MS, MPH, & Karen Burns White, it will focus on Equity in Clinical Trials Participation in recognition of National Minority Cancer Awareness.

ms.spr.ly/6016cxYAY

Full house today at our #USCAP2024 symposium! Thank you Korentzelos Dimitris, Stuart Schnitt & Adam L. Booth, MD for making a strong case for using #AI in routine #pathology practice to help improve #cancer care. Dana-Farber WUSM Pathology & Immunology UPMC USCAP #digitalpathology #cancer diagnostics

Goodbye #USCAP2024 ! Thank you to the hundreds of visitors who came for a demo, chat & ☕ at the booth or clinical sessions & to the trailblazing researchers who made the case for deploying #AI in #patholgoy TODAY! Korentzelos Dimitris Stuart Schnitt Adam L. Booth, MD Zaibo Li USCAP

Young survivors of #BreastCancer face difficult decisions about their future #fertility beginning at the time of diagnosis. A study from Kimia Sorouri, MD, MPH et al explores post-cancer conception and pregnancy experiences for these survivors.

acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn…

#IWD2024

What happens when #hereditarycancer testing identifies two pathogenic variants? We compared cancer risk in >600 individuals with double PVs to those with a single PV in this publication with Dana-Farber. hubs.ly/Q02qphlm0 #genechat #genechat pubs @nbagaglu Brittany Bychkovsky, MD

Our study at the Dana-Farber has been recently published in Genetics in Medicine Open! It is such a pleasure to be a member of the Dana-Farber Cancer Genetics&Prevention family and to work with the Ambry Genetics team! #hereditarycancer Carrie Horton Brittany Bychkovsky, MD Huma Rana, MD, MPH judy garber

World experts in breast cancer brain metastases:
'We suggest default inclusion of pts with BrMs into clinical trials of ADCs.'

But also, intracranial response rates over 30% for both ADCs which brings so much hope for an entire drug class for the treatment of CNS metastases!

🎉Congratulations to Dr. Nelly Polyak on her election to the esteemed American Academy of Arts and Sciences! Your contributions to academia and #CancerResearch are truly remarkable! Polyak Lab

Our CA: A Cancer Journal for Clinicians review on Agnostic ADCs among the top cited articles of 2022-2023! acsjournals.onlinelibrary.wiley.com/doi/10.3322/ca…

Paolo Tarantino 3. if a pt has progressive brain mets and you are planning a switch to an ADC anyways, strongly consider deferring RT to see if the ADC itself will exert intracranial activity - best way to avoid radionecrosis is to avoid RT when systemic tx is a reasonable option

T-DXd is the premier ADC for the treatment of pts with HER2+ MBC BrMs.

The analysis underscores the pressing need to investigate T-DXd in HER2-low BrMs, active HER2+ BrMs across solid tumors, and LMD.
We suggest default inclusion of pts with BrMs into clinical trials of ADCs.

Impressive intracranial activity of both T-DXd (65%) and T-DM1 (34%) for HER2+ brain metastases.

🎙️ Don’t miss the accompanying podcast, where G Curigliano MD PhD and I had the opportunity to interview Sara Hurvitz and Nancy Lin, MD to discuss the results.

Spotify Link: open.spotify.com/episode/2JO8wQ…

Antibody–drug conjugates are active in patients with HER2+ breast cancer brain metastases: where do we go from here? Read the editorial on the brain mets analysis from DB03 by Sarah Sammons (Dr Sarah Sammons) and Nancy Lin (@nlinmd) from Dana-Farber’s Breast Oncology Center. esmoopen.com/article/S2059-…

Out in ESMO Open the intracranial activity of T-DXd vs T-DM1 in the DESTINY-Breast03 phase 3 trial. Among patients with active brain mets, IC-ORR was 65.7% with T-DXd vs 34.3% with T-DM1. Accompanied by a podcast 🎙️ & an editorial by Dr Sarah Sammons Nancy Lin, MD. esmoopen.com/article/S2059-…

Insightful discussion on optimizing post neoadjuvant treatment in patients with early #BreastCancer achieving pathologic complete response in Journal of Clinical Oncology from Carmine Valenza Dario Trapani Sibylle Loibl #StephenChia Harold J. Burstein, MD, PhD, FASCO and G Curigliano MD PhD
Read it here👇
pubmed.ncbi.nlm.nih.gov/38569132/

The unmissable Harvard University breast cancer course is coming back on July 11-12, featuring a terrific faculty and a keynote lecture by Aleix Prat #PrecisionOncology. Make sure to join us, in person or virtually! cmecatalog.hms.harvard.edu/breast-cancer-…

New report on the risk of radiation necrosis with concurrent ADCs + brain RT. Incidence of symptomatic radiation necrosis was 27% with concurrent vs. 11% with non-concurrent ADC/RT (p=0.014). Important to temporarily stop the ADC before pursuing brain RT. link.springer.com/article/10.100…

Check out Dana-Farber’s recent Momentum article highlighting the #ETHANtrial , led by Jose Pablo Leone, MD, which is aimed at revolutionizing care for #MaleBreastCancer .
📍The trial is open at sites across the US. #BreastCancerInMen Translational Breast Cancer Research Consortium
More here👇
physicianresources.dana-farber.org/news/breast-ca…